IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	Lu et al.	GROUP ART UNIT:	1617
SERIAL NO.:	10/683,943	CONFIRMATION NO.:	2772
EXAMINER:	Claytor	ATTORNEY DOCKET NO.:	01419/2/US
FILED:	October 10, 2003		(PC 27793A)

TITLE: DERMAL DELIVERY OF A WATER-SOLUBLE SELECTIVE CYCLOOXYGENASE-2 INHIBITOR

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 28, 2006

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office action of June 15, 2006, regarding the above-identified application, please consider the following remarks.

Applicants elect the invention of Group I (claims 1 (in part), 2, 3, and 7-22), and acknowledge the Office's remarks regarding rejoinder of process claims depending from the elected product claims upon allowability of the elected claims. Applicants elect parecoxib sodium as the water-soluble active agent, and elect glyceryl monolaurate as the skin permeation enhancer. Claims 1-3, 7-13, 15-18, 21, and 22 read on the elected species.

Applicants submit that the present invention is now in condition for allowance. Early allowance of all pending claims is respectfully solicited.

Respectfully submitted,

Patricia K. Fitzsimmons
Registration No. 52,894

Pharmacia Corporation
Post Office Box 1027
St. Louis, MO 63006
Telephone: 314.274.1490
Facsimile: 314.274.9095